<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02331940</url>
  </required_header>
  <id_info>
    <org_study_id>COPDTIOT100</org_study_id>
    <nct_id>NCT02331940</nct_id>
  </id_info>
  <brief_title>Tiotropium Respimat Versus HandiHaler on SaO2 and Sleep in COPD Patients</brief_title>
  <official_title>Tiotropium Respimat Soft Mist Inhaler Versus HandiHaler to Improve Sleeping Oxygen Saturation and Sleep Quality in COPD.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Crete</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Crete</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study was to compare the tiotropium Respimat Soft Mist Inhaler and the
      HandiHaler in terms of their effects on sleeping oxygen saturation (SaO2) and sleep quality
      in patients with COPD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients with chronic obstructive pulmonary disease (COPD) have poor sleep quality as a
      result of various alterations in oxygenation parameters and sleep macro- and
      micro-architecture. We aimed to compare the tiotropium Respimat Soft Mist Inhaler and the
      HandiHaler in terms of their effects on sleeping oxygen saturation (SaO2) and sleep quality
      in patients with COPD. In a randomized, parallel-group trial involving 200 patients with mild
      to moderate COPD (resting arterial oxygen tension &gt;60 mmHg while awake), we compared the
      effects of 6 months' treatment with the two devices on sleeping SaO2 and sleep quality.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sleeping Oxygen Saturation</measure>
    <time_frame>6 months after treatment initiation</time_frame>
    <description>Mean sleeping oxygen saturation (%)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sleep Quality</measure>
    <time_frame>6 months after treatment initiation</time_frame>
    <description>Sleep quality, meaning the architecture of sleep (amount of the different sleep stages across the sleep episode),consists of sleep efficiency (%) (total sleep time - TST divided by the total time in bed and multiplied by 100), REM (%TST) (rapid eye movement sleep divided by TST and multiplied by 100) and NREM (%TST) (non-rapid eye movement sleep divided by TST and multiplied by 100).
NORMAL RANGES Sleep efficiency: Normal is approximately 85 to 90% or higher. NREM (%TST): 75-80% REM (%TST) normally occupies about 20-25% of sleep time.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sleepiness</measure>
    <time_frame>6 months after treatment initiation</time_frame>
    <description>Sleepiness - Epworth Sleepiness Scale (ESS) score (range 0-24, higher values indicate worse outcome, &gt;10 indicates sleepiness, &gt;16 excessive sleepiness)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization Rate</measure>
    <time_frame>6 months after treatment initiation</time_frame>
    <description>Number of patients needed hospitalization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Handihaler</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tiotropium was delivered by the HandiHaler® device, a single-dose dry powder inhaler</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Respimat</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tiotropium was delivered via the Respimat® Soft Mist Inhaler,</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tiotropium</intervention_name>
    <description>Comparison of the effect of tiotropium delivered by the Respimat Soft Mist Inhaler versus the HandiHaler on sleeping oxygen saturation and sleep quality in patients with COPD.</description>
    <arm_group_label>Handihaler</arm_group_label>
    <arm_group_label>Respimat</arm_group_label>
    <other_name>Spiriva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Handihaler</intervention_name>
    <description>Inhalation via the HandiHaler once daily</description>
    <arm_group_label>Handihaler</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Respimat</intervention_name>
    <description>Inhalation via the Respimat once daily</description>
    <arm_group_label>Respimat</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients aged &gt;=40 years old

          -  current or ex-smokers with a smoking history of at least 10 pack-years

          -  mild to moderate stable COPD (Global Initiative for Chronic Obstructive Lung Disease
             [GOLD] Stage I and II according to the 2010 GOLD guidelines (a post-bronchodilator
             forced expiratory volume in the first second (FEV1) ≥80% of predicted for stage I and
             50% ≤ FEV1 &lt; 80% of predicted for stage II, with a post-bronchodilator FEV1/forced
             vital capacity (FVC) ratio &lt;0.70 at screening)

          -  waking arterial oxygen tension (PaO2) ≥60 mmHg

        Exclusion Criteria:

          -  refusal to participate

          -  respiratory tract infection within 4 weeks prior to screening

          -  COPD exacerbations requiring treatment with antibiotics and/or oral corticosteroids
             and/or hospitalization within 6 weeks prior to screening

          -  concomitant pulmonary diseases other than COPD

          -  asthma

          -  evidence of sleep apnea on baseline sleep studies

          -  obesity hypoventilation syndrome

          -  respiratory failure

          -  congestive heart failure

          -  a history of life-threatening arrhythmias

          -  cardiomyopathy

          -  long-QT syndrome or QTc &gt;450 ms at screening

          -  diabetes

          -  long-term oxygen therapy

          -  symptomatic prostatic hyperplasia

          -  bladder-neck obstruction

          -  moderate/severe renal impairment

          -  urinary retention

          -  narrow-angle glaucoma

          -  family or personal history of mental illness

          -  drug or alcohol abuse

          -  severe cognitive impairment

          -  concurrent oncological diseases

          -  history of narcolepsy or restless legs syndrome

          -  known history of alpha-1 antitrypsin deficiency

          -  participation in the active phase of a supervised pulmonary rehabilitation program

          -  hypersensitivity to any of the test ingredients

          -  history of adverse reactions to inhaled anticholinergics.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sophia E Schiza, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Crete</affiliation>
  </overall_official>
  <verification_date>February 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 3, 2015</study_first_submitted>
  <study_first_submitted_qc>January 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2015</study_first_posted>
  <results_first_submitted>May 10, 2016</results_first_submitted>
  <results_first_submitted_qc>February 12, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 30, 2017</results_first_posted>
  <last_update_submitted>February 12, 2017</last_update_submitted>
  <last_update_submitted_qc>February 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Crete</investigator_affiliation>
    <investigator_full_name>Izolde Bouloukaki</investigator_full_name>
    <investigator_title>Consultant</investigator_title>
  </responsible_party>
  <keyword>Chronic obstructive pulmonary disease</keyword>
  <keyword>sleeping oxygen saturation</keyword>
  <keyword>sleep quality</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Handihaler</title>
          <description>Tiotropium was delivered by the HandiHaler® device, a single-dose dry powder inhaler
tiotropium: Comparison of the effect of tiotropium delivered by the Respimat Soft Mist Inhaler versus the HandiHaler on sleeping oxygen saturation and sleep quality in patients with COPD.
Handihaler: Inhalation via the HandiHaler once daily</description>
        </group>
        <group group_id="P2">
          <title>Respimat</title>
          <description>Tiotropium was delivered via the Respimat® Soft Mist Inhaler,
tiotropium: Comparison of the effect of tiotropium delivered by the Respimat Soft Mist Inhaler versus the HandiHaler on sleeping oxygen saturation and sleep quality in patients with COPD.
Respimat: Inhalation via the Respimat once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="93"/>
                <participants group_id="P2" count="95"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Handihaler</title>
          <description>Tiotropium was delivered by the HandiHaler® device, a single-dose dry powder inhaler
tiotropium: Comparison of the effect of tiotropium delivered by the Respimat Soft Mist Inhaler versus the HandiHaler on sleeping oxygen saturation and sleep quality in patients with COPD.
Handihaler: Inhalation via the HandiHaler once daily</description>
        </group>
        <group group_id="B2">
          <title>Respimat</title>
          <description>Tiotropium was delivered via the Respimat® Soft Mist Inhaler,
tiotropium: Comparison of the effect of tiotropium delivered by the Respimat Soft Mist Inhaler versus the HandiHaler on sleeping oxygen saturation and sleep quality in patients with COPD.
Respimat: Inhalation via the Respimat once daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="93"/>
            <count group_id="B2" value="95"/>
            <count group_id="B3" value="188"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.7" spread="11.3"/>
                    <measurement group_id="B2" value="54.9" spread="11.8"/>
                    <measurement group_id="B3" value="54.3" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="55"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="70"/>
                    <measurement group_id="B3" value="133"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Greece</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="95"/>
                    <measurement group_id="B3" value="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sleeping Oxygen Saturation</title>
        <description>Mean sleeping oxygen saturation (%)</description>
        <time_frame>6 months after treatment initiation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Handihaler</title>
            <description>Tiotropium was delivered by the HandiHaler® device, a single-dose dry powder inhaler
tiotropium: Comparison of the effect of tiotropium delivered by the Respimat Soft Mist Inhaler versus the HandiHaler on sleeping oxygen saturation and sleep quality in patients with COPD.
Handihaler: Inhalation via the HandiHaler once daily</description>
          </group>
          <group group_id="O2">
            <title>Respimat</title>
            <description>Tiotropium was delivered via the Respimat® Soft Mist Inhaler,
tiotropium: Comparison of the effect of tiotropium delivered by the Respimat Soft Mist Inhaler versus the HandiHaler on sleeping oxygen saturation and sleep quality in patients with COPD.
Respimat: Inhalation via the Respimat once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Sleeping Oxygen Saturation</title>
          <description>Mean sleeping oxygen saturation (%)</description>
          <units>percentage of Oxygen Saturation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.4" spread="2.4"/>
                    <measurement group_id="O2" value="94.4" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.88</p_value>
            <p_value_desc>p&lt;0.05 was considered statistically significant</p_value_desc>
            <method>t-test, 1 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Sleep Quality</title>
        <description>Sleep quality, meaning the architecture of sleep (amount of the different sleep stages across the sleep episode),consists of sleep efficiency (%) (total sleep time - TST divided by the total time in bed and multiplied by 100), REM (%TST) (rapid eye movement sleep divided by TST and multiplied by 100) and NREM (%TST) (non-rapid eye movement sleep divided by TST and multiplied by 100).
NORMAL RANGES Sleep efficiency: Normal is approximately 85 to 90% or higher. NREM (%TST): 75-80% REM (%TST) normally occupies about 20-25% of sleep time.</description>
        <time_frame>6 months after treatment initiation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Handihaler</title>
            <description>Tiotropium was delivered by the HandiHaler® device, a single-dose dry powder inhaler
tiotropium: Comparison of the effect of tiotropium delivered by the Respimat Soft Mist Inhaler versus the HandiHaler on sleeping oxygen saturation and sleep quality in patients with COPD.
Handihaler: Inhalation via the HandiHaler once daily</description>
          </group>
          <group group_id="O2">
            <title>Respimat</title>
            <description>Tiotropium was delivered via the Respimat® Soft Mist Inhaler,
tiotropium: Comparison of the effect of tiotropium delivered by the Respimat Soft Mist Inhaler versus the HandiHaler on sleeping oxygen saturation and sleep quality in patients with COPD.
Respimat: Inhalation via the Respimat once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Sleep Quality</title>
          <description>Sleep quality, meaning the architecture of sleep (amount of the different sleep stages across the sleep episode),consists of sleep efficiency (%) (total sleep time - TST divided by the total time in bed and multiplied by 100), REM (%TST) (rapid eye movement sleep divided by TST and multiplied by 100) and NREM (%TST) (non-rapid eye movement sleep divided by TST and multiplied by 100).
NORMAL RANGES Sleep efficiency: Normal is approximately 85 to 90% or higher. NREM (%TST): 75-80% REM (%TST) normally occupies about 20-25% of sleep time.</description>
          <units>percentage of time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>sleep efficiency (%)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.2" spread="11.8"/>
                    <measurement group_id="O2" value="79.1" spread="13.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NREM (%TST)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.3" spread="4.9"/>
                    <measurement group_id="O2" value="85.3" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>REM (%TST)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.7" spread="4.9"/>
                    <measurement group_id="O2" value="14.7" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sleepiness</title>
        <description>Sleepiness - Epworth Sleepiness Scale (ESS) score (range 0-24, higher values indicate worse outcome, &gt;10 indicates sleepiness, &gt;16 excessive sleepiness)</description>
        <time_frame>6 months after treatment initiation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Handihaler</title>
            <description>Tiotropium was delivered by the HandiHaler® device, a single-dose dry powder inhaler
tiotropium: Comparison of the effect of tiotropium delivered by the Respimat Soft Mist Inhaler versus the HandiHaler on sleeping oxygen saturation and sleep quality in patients with COPD.
Handihaler: Inhalation via the HandiHaler once daily</description>
          </group>
          <group group_id="O2">
            <title>Respimat</title>
            <description>Tiotropium was delivered via the Respimat® Soft Mist Inhaler,
tiotropium: Comparison of the effect of tiotropium delivered by the Respimat Soft Mist Inhaler versus the HandiHaler on sleeping oxygen saturation and sleep quality in patients with COPD.
Respimat: Inhalation via the Respimat once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Sleepiness</title>
          <description>Sleepiness - Epworth Sleepiness Scale (ESS) score (range 0-24, higher values indicate worse outcome, &gt;10 indicates sleepiness, &gt;16 excessive sleepiness)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.5" spread="5.9"/>
                    <measurement group_id="O2" value="6.1" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospitalization Rate</title>
        <description>Number of patients needed hospitalization</description>
        <time_frame>6 months after treatment initiation</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Handihaler</title>
            <description>Tiotropium was delivered by the HandiHaler® device, a single-dose dry powder inhaler
tiotropium: Comparison of the effect of tiotropium delivered by the Respimat Soft Mist Inhaler versus the HandiHaler on sleeping oxygen saturation and sleep quality in patients with COPD.
Handihaler: Inhalation via the HandiHaler once daily</description>
          </group>
          <group group_id="O2">
            <title>Respimat</title>
            <description>Tiotropium was delivered via the Respimat® Soft Mist Inhaler,
tiotropium: Comparison of the effect of tiotropium delivered by the Respimat Soft Mist Inhaler versus the HandiHaler on sleeping oxygen saturation and sleep quality in patients with COPD.
Respimat: Inhalation via the Respimat once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Hospitalization Rate</title>
          <description>Number of patients needed hospitalization</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="93"/>
                <count group_id="O2" value="95"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Handihaler</title>
          <description>Tiotropium was delivered by the HandiHaler® device, a single-dose dry powder inhaler
tiotropium: Comparison of the effect of tiotropium delivered by the Respimat Soft Mist Inhaler versus the HandiHaler on sleeping oxygen saturation and sleep quality in patients with COPD.
Handihaler: Inhalation via the HandiHaler once daily</description>
        </group>
        <group group_id="E2">
          <title>Respimat</title>
          <description>Tiotropium was delivered via the Respimat® Soft Mist Inhaler,
tiotropium: Comparison of the effect of tiotropium delivered by the Respimat Soft Mist Inhaler versus the HandiHaler on sleeping oxygen saturation and sleep quality in patients with COPD.
Respimat: Inhalation via the Respimat once daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="93"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="95"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Clinical Trials</name_or_title>
      <organization>University of Crete</organization>
      <phone>2810394824 ext 0030</phone>
      <email>izolthi@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

